Literature DB >> 3719596

Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy.

W R Klein, P A Steerenberg, F Poelma, E vd Wiel, V P Rutten, W Misdorp, W H de Jong, E J Ruitenberg.   

Abstract

Lymphocyte stimulation with Con A and specific immune reactivity to BCG (antibody formation to BCG and DTH reaction to PPD) were determined in BCG-treated, surgically treated and untreated cows with ocular squamous cell carcinoma. In tumor-bearing cows the Con A-induced proliferation of lymphocytes was reduced when compared to healthy controls. This suppression consisted of a reduced blastogenic response to Con A of lymphocytes from tumor-bearing cows, and the presence of a factor in the sera of these animals, as these sera suppressed the blastogenic response of lymphocytes from healthy cows. BCG had only a minor influence on the suppressive activity. Antibodies to BCG were demonstrated in 50% of the BCG-treated animals. The formation of antibodies was not influenced by intradermal injection of PPD of Mycobacterium bovis. Absorption of a BCG antibody containing serum with BOSCC tumor extracts did not reveal the existence of cross reacting antigens between BCG and BOSCC. Pretherapeutic and posttherapeutic Con A reactivity could not be correlated with clinical response. Of the 30 BCG treated cows 29 developed a positive DTH reaction to PPD. Correlation between clinical response and immune reactivity was seen only with regard to the DTH reaction to PPD: this reaction remained positive for a longer period after treatment in animals with a favorable clinical outcome than in nonresponding animals.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3719596     DOI: 10.1007/bf00199120

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  54 in total

1.  Studies on bovine ocular squamous carcinoma (cancer eye). I. Pathological anatomy and historical review.

Authors:  W O RUSSELL; E S WYNNE; G S LOQUVAM
Journal:  Cancer       Date:  1956 Jan-Feb       Impact factor: 6.860

2.  Persistent papillomatosis associated with immunodeficiency.

Authors:  J R Duncan; L B Corbeil; D H Davies; R D Schultz; R H Whitlock
Journal:  Cornell Vet       Date:  1975-04

Review 3.  Immunotherapy from malignant disease.

Authors:  J E Goodnight; D L Morton
Journal:  Annu Rev Med       Date:  1978       Impact factor: 13.739

4.  Tumor-specific antigen solubilized by hypertonic potassium chloride.

Authors:  M S Meltzer; E J Leonard; H J Rapp; T Borsos
Journal:  J Natl Cancer Inst       Date:  1971-09       Impact factor: 13.506

Review 5.  Immunotherapy of superficial bladder cancer.

Authors:  A Shapiro; D Kadmon; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1982-11       Impact factor: 7.450

Review 6.  Serial immune function testing to predict clinical disease relapse in patients with solid tumors.

Authors:  D P Braun; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 7.  Bacillus Calmette-Guérin as an anti-tumor agent. The interaction with cells of the mammalian immune system.

Authors:  M Davies
Journal:  Biochim Biophys Acta       Date:  1982-04-29

8.  Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer.

Authors:  M F McKneally; C Maver; L Lininger; H W Kausel; J B McIlduff; T M Older; E D Foster; R D Alley
Journal:  J Thorac Cardiovasc Surg       Date:  1981-04       Impact factor: 5.209

9.  Serum blocking factors in bovine ocular squamous cell carcinoma demonstrated by inhibition of erythrocyte rosette augmentation.

Authors:  V K Kuchroo; W J Halliday; P A Jennings; P B Spradbrow
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

10.  Immunological monitoring and immunotherapy in carcinoma of the lung.

Authors:  J L Weese; R B Herberman; E Perlin; M Mills; W Heims; J Blom; D Green; J Reid; S Bellinger; I Law; J L McCoy; J H Dean; G B Cannon; J Djeu
Journal:  Int J Cancer       Date:  1976-12-15       Impact factor: 7.396

View more
  5 in total

1.  Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.

Authors:  A P van der Meijden; P A Steerenberg; I M van Hoogstraaten; J A Kerckhaert; L M Schreinemachers; E J Harthoorn-Lasthuizen; A M Hagenaars; W H de Jong; F M Debruijne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study.

Authors:  V P Rutten; W R Klein; W A De Jong; W Misdorp; W Den Otter; P A Steerenberg; W H De Jong; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

Authors:  M J Stassar; P D Vegt; P A Steerenberg; A P van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; W den Otter
Journal:  Urol Res       Date:  1994

4.  Immunotherapy of bovine ocular squamous cell carcinoma by repeated intralesional injections of live bacillus Calmette-Guérin (BCG) or BCG cell walls.

Authors:  V P Rutten; W R Klein; W A De Jong; W Misdorp; P A Steerenberg; W H De Jong; W Den Otter; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.

Authors:  A P van der Meijden; W H de Jong; E C de Boer; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.